Nicox SA
Company Profile
Business description
Nicox SA is an international ophthalmology company developing solutions to help preserve vision and improve ocular health. It is developing a portfolio of treatments targeting glaucoma, diseases of the anterior segment and retinal diseases. A drug candidate (NCX 470) in phase 3 clinical development designed to reduce intraocular pressure ("IOP") in patients with open-angle glaucoma or ocular hypertension. A drug candidate (NCX 1728) in preclinical development for retinal diseases and glaucoma, derived from Nicox's proprietary nitric oxide (NO)-donating research platform. Its products are ZERVIATE, VYZULTA, Naproxcinod, etc.
Contact
Rue Evariste Galois
Emerald Square, Batiment C
Sundesk Sophia Antipolis
Biot06410
FRAT: +33 497245300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
5
Stocks News & Analysis
stocks
Why don’t good returns guarantee a 5-star rating?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,937.80 | 59.50 | -0.66% |
| CAC 40 | 8,216.78 | 135.22 | -1.62% |
| DAX 40 | 26,045.37 | 553.27 | -2.08% |
| Dow JONES (US) | 50,759.42 | 848.75 | -1.64% |
| FTSE 100 | 10,689.87 | 191.68 | -1.76% |
| HKSE | 23,263.03 | 245.14 | -1.04% |
| NASDAQ | 24,328.38 | 181.38 | -0.74% |
| Nikkei 225 | 59,091.80 | 231.37 | 0.39% |
| NZX 50 Index | 14,264.29 | 42.67 | -0.30% |
| S&P 500 | 7,340.53 | 76.06 | -1.03% |
| S&P/ASX 200 | 8,827.00 | 56.20 | -0.63% |
| SSE Composite Index | 3,574.03 | 10.55 | -0.29% |